Scoop has an Ethical Paywall
Licence needed for work use Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Update: Trilogy shares slump on FY2017 guidance

Thursday 22 September 2016 04:14 PM

UPDATE: Trilogy International shares slump on FY2017 guidance

(Updates to show shares dropped, adds broker comment)

By Edwin Mitson

Sept. 22 (BusinessDesk) - Shares of Trilogy International, which have almost tripled in the past 12 months, dropped to a three-month low after the skincare and home fragrance company raised its full-year sales guidance for a second time, suggesting investors were hoping for even better news at today's annual meeting in Auckland.

The stock dropped 14 percent to $4.01, and earlier sank as much as 18 percent to $3.81, trimming their gain in the past 12 months to 47 percent.

Daniel Metcalfe, senior investment advisor at OMF in Auckland was sceptical about the sell-off, "I think it's a bit of profit-taking. The guidance they've given seems pretty bullish to me. They're raising the bar yet again. But then again, they've had such fundamental growth over the last two years, perhaps investors expected more."

The company told shareholders at their annual meeting in Auckland that it expects 2017 revenue of $100 million to $110 million, a gain of between 20 percent and 32 percent over 2016's $83 million of sales.

Trilogy's brands include Ecoya candles, Trilogy and Goodness. It also owns CS & Co, the country's largest independent importer and distributor of fragrances and toiletries, which it bought in August 2015.

Earnings before interest, taxation, amortisation and depreciation are expected to be $19 million to $21 million, an increase of between 17 and 29 percent. That compares with ebitda of $16.3 million in the 2016 full year.

Advertisement - scroll to continue reading

If Trilogy International achieves $100 million in revenue it would have almost tripled sales in just two years, mainly through the CS & Co acquisition. CS & Co delivered $28.6 million in revenue in the seven and a half months it contributed to Trilogy's FY2016.

Also at the AGM, chairman Geoff Ross confirmed that an application to list on the ASX through an ASX foreign exempt listing had been submitted, which subject to approval, will see Trilogy International listed on the ASX by the end of October.

(BusinessDesk)


© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.